vs
Side-by-side financial comparison of Alliance Laundry Holdings Inc. (ALH) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
Alliance Laundry Holdings Inc. is the larger business by last-quarter revenue ($437.6M vs $247.1M, roughly 1.8× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 7.5%, a 3.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 13.9%). Alliance Laundry Holdings Inc. produced more free cash flow last quarter ($87.0M vs $29.1M).
Alliance Laundry Systems LLC is an American provider of commercial laundry systems. The company designs, manufactures, and markets a line of commercial and industrial laundry equipment under various brands in over 100 countries. Among the company's products are washers, drying tumblers and ironers for the coin laundry, multi-housing laundries, institutional laundries and laundries for consumer residences. Alliance Laundry Systems manufactures products under the brands Speed Queen, Primus, Hue...
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ALH vs ANIP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $437.6M | $247.1M |
| Net Profit | $32.9M | $27.5M |
| Gross Margin | 37.0% | — |
| Operating Margin | 19.5% | 14.1% |
| Net Margin | 7.5% | 11.1% |
| Revenue YoY | 13.9% | 29.6% |
| Net Profit YoY | 620.3% | 367.5% |
| EPS (diluted) | $0.19 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $247.1M | ||
| Q3 25 | $437.6M | $227.8M | ||
| Q2 25 | — | $211.4M | ||
| Q1 25 | — | $197.1M | ||
| Q4 24 | — | $190.6M | ||
| Q3 24 | $384.3M | $148.3M | ||
| Q2 24 | — | $138.0M | ||
| Q1 24 | — | $137.4M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | $32.9M | $26.6M | ||
| Q2 25 | — | $8.5M | ||
| Q1 25 | — | $15.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | $-6.3M | $-24.2M | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $18.2M |
| Q4 25 | — | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 14.1% | ||
| Q3 25 | 19.5% | 15.9% | ||
| Q2 25 | — | 6.6% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | 18.7% | -13.8% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 14.8% |
| Q4 25 | — | 11.1% | ||
| Q3 25 | 7.5% | 11.7% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | -5.4% | ||
| Q3 24 | -1.6% | -16.3% | ||
| Q2 24 | — | -1.7% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | $1.14 | ||
| Q3 25 | $0.19 | $1.13 | ||
| Q2 25 | — | $0.36 | ||
| Q1 25 | — | $0.69 | ||
| Q4 24 | — | $-0.45 | ||
| Q3 24 | $-0.04 | $-1.27 | ||
| Q2 24 | — | $-0.14 | ||
| Q1 24 | — | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.2M | $285.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-136.4M | $540.7M |
| Total Assets | $2.9B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $285.6M | ||
| Q3 25 | $136.2M | $262.6M | ||
| Q2 25 | — | $217.8M | ||
| Q1 25 | — | $149.8M | ||
| Q4 24 | — | $144.9M | ||
| Q3 24 | $128.4M | $145.0M | ||
| Q2 24 | — | $240.1M | ||
| Q1 24 | — | $228.6M |
| Q4 25 | — | $540.7M | ||
| Q3 25 | $-136.4M | $505.8M | ||
| Q2 25 | — | $436.8M | ||
| Q1 25 | — | $418.6M | ||
| Q4 24 | — | $403.7M | ||
| Q3 24 | $-284.6M | $405.9M | ||
| Q2 24 | — | $455.8M | ||
| Q1 24 | — | $452.0M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | $2.9B | $1.4B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $920.8M | ||
| Q1 24 | — | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $116.8M | $30.4M |
| Free Cash FlowOCF − Capex | $87.0M | $29.1M |
| FCF MarginFCF / Revenue | 19.9% | 11.8% |
| Capex IntensityCapex / Revenue | 6.8% | 0.5% |
| Cash ConversionOCF / Net Profit | 3.55× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $30.4M | ||
| Q3 25 | $116.8M | $44.1M | ||
| Q2 25 | — | $75.8M | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $12.5M | ||
| Q2 24 | — | $17.4M | ||
| Q1 24 | — | $18.3M |
| Q4 25 | — | $29.1M | ||
| Q3 25 | $87.0M | $38.0M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | — | 11.8% | ||
| Q3 25 | 19.9% | 16.7% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.4% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 6.8% | 2.7% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | 1.10× | ||
| Q3 25 | 3.55× | 1.66× | ||
| Q2 25 | — | 8.87× | ||
| Q1 25 | — | 2.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALH
| Equipment Product Or Service | $275.7M | 63% |
| Other | $106.8M | 24% |
| Service Parts | $33.1M | 8% |
| Equipment Financing | $12.6M | 3% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
